Stephanie Eisenbarth and Adam Williams prepare peanuts for allergy research in their lab
Northwestern University
Research indicates that common asthma treatments may offer protection against anaphylaxis, a severe allergic reaction. The drug Zileuton, traditionally used for asthma, is now being considered for individuals facing serious food allergies.
Despite the prevalence of food allergies, it can be challenging to foresee the risk of anaphylaxis for an individual. Scientists are investigating why some individuals with positive food allergen tests do not show symptoms, while others have severe, potentially deadly reactions.
“Our aim is to discover methods to help individuals with symptomatic food allergies manage their reactions to allergens,” states Stephanie Eisenbarth from Northwestern University, Illinois.
Eisenbarth and her research team anticipated that mice exposed to peanuts would experience anaphylaxis. They administered a single oral dose of Zileuton to a group of 5-10 mice sensitized to peanut allergens approximately one hour prior to feeding them peanut extract. The control group did not receive any medication. Observations revealed that almost all Zileuton-treated mice showed no symptoms of anaphylaxis, whereas the control group exhibited clear signs of it.
Most dietary proteins are usually broken down, but some can be actively absorbed through the intestines and enter the bloodstream directly. In individuals with severe allergies, these proteins can trigger immune responses, leading to anaphylaxis.
During allergic reactions, the body releases chemicals known as leukotrienes. The researchers found that leukotrienes play a role in the number of intact proteins that penetrate the intestine. They also identified a gene called DPEP1 that is crucial in regulating leukotriene levels.
One significant action of Zileuton is inhibiting the enzyme five lipoxygenase, essential for leukotriene production. Administering this drug to mice lowered leukotriene levels, while DPEP1 also suppressed remaining leukotrienes, preventing allergen absorption and halting anaphylaxis in susceptible mice. A single dose of Zileuton cut the anaphylaxis rate by 95%.
“We can differentiate between mice that respond to food allergens and those that do not. We are now evaluating whether the same asthma medications can limit allergen absorption in the intestines of people with food allergies.”
Jorge Emiliano Gomez Medellin from the University of Chicago suggests that these straightforward tablets might significantly alleviate the consequences of accidental allergen exposure. He added that while Zileuton could potentially inhibit the absorption of food allergens, it won’t alter an individual’s underlying sensitivity over time.
“Nonetheless, Zileuton could be a valuable tool in combating food allergies,” he concludes.
Source: www.newscientist.com
